Overview

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Status:
Terminated

Trial end date:
2017-05-01

Target enrollment:

Participant gender:

Summary

A Two-arm, Phase 1b/2 Study of duvelisib Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Infinity Pharmaceuticals, Inc.
SecuraBio

Treatments:

Obinutuzumab
Rituximab